Creating new drugs to target estrogen receptors for glioblastoma treatment
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
This study is looking for ways to use new medications that target a specific estrogen receptor to help treat glioblastoma, a tough type of brain cancer, while keeping side effects low, and patients may have a chance to join trials to see how well these new treatments work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11001201 on NIH RePORTER |
What this research studies
This research focuses on developing new and potent estrogen receptor beta (ERβ) agonists to treat glioblastoma, a highly aggressive brain cancer. The study aims to leverage the protective role of female sex hormones against cancer progression while minimizing the risks associated with traditional estrogen treatments. By utilizing advanced techniques, including CRISPR technology, the researchers will explore the therapeutic potential of selective ERβ agonists that can effectively suppress tumor growth without the adverse effects linked to existing treatments. Patients may have the opportunity to participate in trials assessing the safety and efficacy of these novel compounds.
Who could benefit from this research
Good fit: Ideal candidates for participation would include adults diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with glioblastoma who have already exhausted all treatment options or those with contraindications to estrogen therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for glioblastoma patients.
How similar studies have performed: While the approach of targeting estrogen receptors in glioblastoma is relatively novel, previous studies have shown promise in using hormone-based therapies for other cancers.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Vadlamudi, Ratna K — University of Texas Hlth Science Center
- Study coordinator: Vadlamudi, Ratna K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.